Back to top
more

AVEO Pharmaceuticals, Inc. (AVEO)

(Delayed Data from NSDQ)

$0.94 USD

0.94
1,186,754

+0.04 (4.01%)

Updated May 3, 2019 04:00 PM ET

After-Market: $0.91 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study

Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.

AnaptysBio Shares Up on Positive Top-Line Psoriasis Data

AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.

Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev

Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.

Immunomedics' Trodelvy Gets Orphan Drug Tag for Glioblastoma

Immunomedics' (IMMU) lead product candidate, Trodelvy, gets FDA orphan drug status for the treatment of adult and pediatric patients with glioblastoma.

Alexion's Ultomiris Gets FDA Approval for New Formulation

Alexion (ALXN) gets FDA approval for Ultomiris 100 mg/mL, a new advanced formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Canopy Growth (CGC) Looks Good: Stock Adds 8.5% in Session

Canopy Growth (CGC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Axovant's Gene Therapy Gets Rare Pediatric Disease Status

The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.

Amgen Down on Unsatisfactory Heart Failure Drug Study Results

Amgen (AMGN) with partners post top-line data from the phase III GALACTIC-HF study on omecamtiv mecarbil, which is being evaluated for heart failure with reduced ejection fraction. Stock falls.

Novo Nordisk Raises Sales & Operating Profit Outlook for 2020

Novo Nordisk (NVO) raises 2020 sales and operating profit outlook at constant exchange rates.

BioMarin (BMRN) Gets FDA Approval for Higher Dose of Palynziq

The FDA approves higher dose (60 mg) of BioMarin's (BMRN) Phenylketonuria drug Palynziq injection. The regulatory nod includes the addition of longer-term efficacy data on Palynziq's label.

Kindred Shares Up on Expansion of Agreement With Vaxart

Kindred (KIN) expands an agreement with Vaxart for the manufacturing of the latter's oral vaccine for COVID-19 and other vaccine candidates.

Iovance Stock Down on Delay in Filing for Melanoma Candidate

Iovance (IOVA) delays its application to the FDA for a tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for the treatment of metastaic melanoma until later in 2021.

Alector (ALEC) Surges: Stock Moves 6.9% Higher

Alector (ALEC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Increased Earnings Estimates Seen for AVEO Pharmaceuticals (AVEO): Can It Move Higher?

AVEO Pharmaceuticals (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

AVEO's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals.

AVEO Acquires Full Global Rights to Ficlatuzumab From Biodesix

AVEO reclaims complete rights to ficlatuzumab from Biodesix for an undisclosed sum. The candidate is being developed for several cancer indications.

AVEO (AVEO) Up 20.7% Since Last Earnings Report: Can It Continue?

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AVEO's NDA for Fotivda on Track, FDA Verdict Due Next Year

AVEO Pharmaceuticals (AVEO) seeks an FDA nod for Fotivda in the United States to treat relapsed or refractory RCC. A decision from the regulatory agency is expected on Mar 31, 2021.

Rhythm (RYTM) Soars: Stock Adds 9.4% in Session

Rhythm (RYTM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Kura Oncology (KURA) Looks Good: Stock Adds 6.8% in Session

Kura Oncology (KURA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Aeglea (AGLE) Looks Good: Stock Adds 5.8% in Session

Aeglea (AGLE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

    AVEO (AVEO) Upgraded to Buy: What Does It Mean for the Stock?

    AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates

    AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.

    AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates

    AVEO (AVEO) delivered earnings and revenue surprises of 17.65% and -49.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: AVEO Pharmaceuticals (AVEO) Q2 Earnings Expected to Decline

    AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.